Organisation paid for research Program year 2024 Source: CMS Open Payments

Pharmaceutical Research Organizatio

Neither a doctor nor a teaching hospital

Research payments

$2,742,807

912 payments

Through program year 2024, Pharmaceutical Research Organizatio is reported as receiving $2,742,807 in research payments, across 912 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$2,740	4
2023	Research	$31,484	12
2022	Research	$836,842	465
2021	Research	$1,631,057	386
2020	Research	$194,164	39
2019	Research	$46,520	6

Breakdown

Who paid Research payments · program years 2019–2024

GlaxoSmithKline, LLC. $2,633,086 900 payments
AstraZeneca Pharmaceuticals LP $109,721 12 payments

Studies the money was for Research payments · program years 2019–2024

Study name not reported $1,626,214 387 payments
A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra $530,949 310 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $245,203 149 payments
Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $152,699 42 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $109,721 12 payments
A Phase III, Observer-Blind, Randomized, Multi-Country Study to Assess $78,020 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.